Drug Store News - Eli Lilly - Supplier News - progresses in development of Cymbalta - Brief Article
Eli Lilly is one step closer to gaining Food and Drug Administration approval for Cymbalta (duloxetine HCI) for treating depression. The company received an approvable letter for the serotonin and norepinephrine reuptake inhibitor Oct. 1. Final approval is contingent upon the resolution of manufacturing issues at the company’s Indianapolis manufacturing plant, including a pre-approval site inspection and the completion of final labeling.
Related Results
Lilly prepares for Cymbalta launch
Duloxetine lifts arthritis pain, aids cognition.(Psychosomatic Medicine)
Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized An…
FDA Approves Cymbalta(R) for Treatment of Generalized Anxiety Disorder
Duloxetine improves depression, pain, cognition.
The company also received an approvable letter for Cymbalta for use in treating stress urinary incontinence; however, additional studies are required.
COPYRIGHT 2003 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2008 Gale, Cengage Learning
